Interleukin‐12: Murine Models of a Potent Antitumor Agent a
暂无分享,去创建一个
J. Wigginton | L. Luistro | R. Wiltrout | M. Brunda | A. Palleroni | R. Wright | J. A. Hendrzak | Leonid Rumennik
[1] J. Franco,et al. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. , 1996, Journal of the National Cancer Institute.
[2] H. Fujiwara,et al. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. , 1995, Cancer research.
[3] L. Zitvogel,et al. Role of interleukin-12 (IL12) as an anti-tumour agent: experimental biology and clinical application. , 1995, Research in immunology.
[4] H. Fujiwara,et al. A sequence of cellular and molecular events involved in IL12-induced tumour regression. , 1995, Research in immunology.
[5] L. Zitvogel,et al. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. , 1995, Journal of immunology.
[6] H. Fujiwara,et al. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. , 1995, International immunology.
[7] L. Zitvogel,et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. , 1995, Journal of immunology.
[8] Hendrzak Ja,et al. Interleukin-12. Biologic activity, therapeutic utility, and role in disease. , 1995 .
[9] A. Khar,et al. AK-5 tumor-induced expression of interleukin-12: role of IL-12 in NK-mediated AK-5 regression. , 1995, Cellular immunology.
[10] R. D'Amato,et al. Inhibition of angiogenesis in vivo by interleukin 12. , 1995, Journal of the National Cancer Institute.
[11] Yao-Tseng Chen,et al. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[12] G. Trinchieri,et al. IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. , 1995, Journal of immunology.
[13] L. Luistro,et al. Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. , 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[14] G. Trinchieri,et al. CD4 T cells inhibit in vivo the CD8‐mediated immune response against murine colon carcinoma cells transduced with interleukin‐12 genes , 1995, European journal of immunology.
[15] G. Trinchieri,et al. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. , 1994, Blood.
[16] A. Cesano,et al. Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach. , 1994, The Journal of clinical investigation.
[17] R. Schreiber,et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. , 1994, Journal of immunology.
[18] G. Trinchieri,et al. B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation , 1994, The Journal of experimental medicine.
[19] G. Trinchieri,et al. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells , 1994, The Journal of experimental medicine.
[20] M. Gately,et al. Antitumor activity of interleukin-12. , 1994, Clinical immunology and immunopathology.
[21] B. Perussia,et al. Effect of human natural killer cells on the metastatic growth of human melanoma xenografts in mice with severe combined immunodeficiency. , 1994, Cancer research.
[22] J. Ritz,et al. Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies , 1993 .
[23] L. Luistro,et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors , 1993, The Journal of experimental medicine.
[24] A. Składanowski,et al. Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. , 1993, Biochemical pharmacology.
[25] R. Dziadziuszko,et al. Interleukin 12 augments natural killer-cell mediated cytotoxicity in hairy cell leukemia. , 1993, Leukemia & lymphoma.
[26] A. Bradley,et al. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. , 1993, Science.
[27] M. Gately,et al. Regulation of human cytolytic lymphocyte responses by interleukin-12. , 1992, Cellular immunology.
[28] P. Familletti,et al. Cloning and expression of murine IL-12. , 1992, Journal of immunology.
[29] M. Gately,et al. IL-12 receptor. II. Distribution and regulation of receptor expression. , 1992, Journal of immunology.
[30] B. Naume,et al. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells. , 1992, Journal of immunology.
[31] P. Familletti,et al. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[32] R. Hewick,et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. , 1991, Journal of immunology.
[33] A. Cesano,et al. Treatment of experimental glioblastoma with a human major histocompatibility complex nonrestricted cytotoxic T cell line. , 1995, Cancer research.
[34] M. Gately,et al. Interleukin-12: a pivotal regulator of cell-mediated immunity. , 1995, Cancer treatment and research.
[35] D. Carvajal,et al. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. , 1994, International immunology.
[36] B. Ksander,et al. IL-12 ABROGATES IMMUNE PRIVILEGE IN THE ANTERIOR CHAMBER OF THE EYE , 1994 .
[37] Simon C Watkins,et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. , 1994, Cancer research.